Infasurf treats and prevents respiratory distress syndrome (RDS). RDS occurs when infants lack surfactant, a natural substance normally produced in the body, which is necessary for lungs to function normally. Infasurf is used exclusively in hospitals with a neonatal intensive care unit (NICU) and is administered by neonatologists, neonatal nurses, neonatal nurse practitioners and respiratory therapists. Infasurf has been used in over 100,000 infants.

Safety Information

Administration of exogenous surfactants, including INFASURF, often rapidly improves oxygenation and lung compliance. Following INFASURF administration, patients should be monitored so that oxygen and ventilatory support can be modified. During dosing with INFASURF, the most common adverse reactions reported in clinical trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), and ETT reflux (21%). These events were generally transient, and not associated with serious complications. If any of these events occur, administration should be interrupted and the infant's condition stabilized.